Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment
Author:
Publisher
Wiley
Subject
Hematology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2007.00930.x/fullpdf
Reference27 articles.
1. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
2. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
3. Thalidomide is an inhibitor of angiogenesis.
4. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
5. Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma;Targeted Oncology;2022-06-30
2. Attainment of a Stringent Complete Response in Multiple Myeloma with Thalidomide Monotherapy;Internal Medicine;2012
3. Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration;European Journal of Haematology;2010-04
4. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib;European Journal of Haematology;2009-12
5. Varicella-Zoster Virus Prophylaxis with Low-Dose Acyclovir in Patients with Multiple Myeloma Treated with Bortezomib;Clinical Lymphoma and Myeloma;2009-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3